"10.1371_journal.pone.0135513","plos one","2015-09-25T00:00:00Z","Anne-Laure Flamar; Vanessa Contreras; Sandra Zurawski; Monica Montes; Nathatlie Dereuddre-Bosquet; Frédéric Martinon; Jacques Banchereau; Roger Le Grand; Gerard Zurawski; Yves Levy","Baylor Institute for Immunology Research, Dallas, Texas, United States of America; Vaccine Research Institute, Créteil, France; INSERM UMR 955, Equipe 16, Créteil, France; CEA, Division of Immuno-Virology, IDMIT Center, Institute for Emerging Diseases and Innovative Therapies, Fontenay-aux-Roses, France; INSERM UMR 1184, Fontenay-aux-Roses, France; Université Paris-Sud 11, Orsay, France; Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America; Assistance Publique-Hôpitaux de Paris, Groupe Henri-Mondor Albert-Chenevier, service dimmunologie clinique, Créteil, France; Université Paris Est, Faculté de médecine, Créteil, France","Conceived and designed the experiments: ALF SZ JB YL RL GZ. Performed the experiments: ALF VC SZ MM NDB FM. Analyzed the data: ALF VC SZ FM RL YL GZ. Contributed reagents/materials/analysis tools: ALF SZ GZ. Wrote the paper: ALF RL YL GZ.","ALF, SZ, JB and GZ are inventors on an issued patent related to the work described in this study. The Baylor Research Institute has patent filings related to the anti-DCIR Gag p24 vaccine described in this paper at various stages in various countries: specifically they are entitled VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED AN ANTIGEN-PRESENTING CELLS with reference numbers 2008214032 Australia, PCT National Phase; 2715044, Canada, PCT National Phase; 10108281.9, Hong Kong, Reregistration of EP/CN; 200880011285.1, China, PCT National Phase; 08728868.4, Germany, France, United Kingdom, EP National Stage; 12164572.5, European Patent Office, Divisional; 200088, Israel, PCT National Phase; 2009-548481, Japan, PCT National Phase; MX/a/2009/008140, Mexico, PCT National Phase; MX/a/2012/002859, Mexico, Divisional; 578696, New Zealand, PCT National Phase; 593450, New Zealand, Divisional; 97104113, Taiwan, Standard; 2009/05347, South Africa, PCT National Phase; 12/024897, 13/234914, 13/872793, 14/045454, USA, Continuation; 13/454404, USA, Divisional. The anti-DCIR Gag p24 vaccine is not currently in clinical development and we confirm that the above patent filing activities do not alter adherence to all PLOS ONE policies on sharing data and materials, as detailed online in your guide for authors. The authors confirm there are no restrictions on sharing of data and/or materials associated with this study other than the requirement for standard Material Transfer Agreements for governing material sharing that would be typical for any academic research institution.","2015","09","Anne-Laure Flamar","ALF",10,TRUE,6,6,7,4,TRUE,TRUE,FALSE,0,NA,FALSE
